信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 2021-11-04 17:00
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China 2021-10-28 08:00
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint 2021-10-18 08:00
Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors 2021-09-30 08:00
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021 2021-09-29 08:00
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions 2021-09-28 08:00
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting 2021-09-27 08:00
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis 2021-09-24 08:00
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC) 2021-09-23 08:00
Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021 2021-09-18 08:00
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021 2021-09-18 08:00
Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021 2021-09-17 08:00
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China 2021-09-08 08:00
Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor) 2021-09-02 08:00
Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021 2021-08-30 08:00
Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs 2021-08-27 08:00
Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint 2021-08-25 20:53
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet 2021-08-18 08:00
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 2021-08-16 08:00
Innovent Announces IBI306 (anti-PCSK-9 antibody) Meets the Primary Endpoint in a Phase 3 Clinical Study for Chinese Heterozygous Familial Hypercholesterolemia 2021-08-12 08:00
1 8 9 10 11 12 17